Research programme: p38 MAP kinase inhibitors - LEO Pharma

Drug Profile

Research programme: p38 MAP kinase inhibitors - LEO Pharma

Alternative Names: p38 MAP kinase inhibitors research programme - LEO Pharma

Latest Information Update: 08 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEO Pharma
  • Class Benzophenones; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 08 Apr 2008 Discontinued - Preclinical for Inflammation in Denmark (unspecified route)
  • 07 Sep 2004 Data presented at the 18th International Symposium on Medicinal Chemistry (ISMC-2004) have been added to the pharmacokinetics and Inflammation pharmacodynamics section
  • 28 Jan 2004 Preclinical trials in Inflammation in Denmark (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top